Geoffroy M, Lemesle M, Kleinclauss A, Mazerbourg S, Batista L, Barberi-Heyob M, Bastogne T, Boireau W, Rouleau A, Dupommier D, Boisbrun M, Comoy C, Flament S, Grillier-Vuissoz I, Kuntz S

Int J Mol Sci. 2022 06 20;23(12):

Transcriptomics and Metabolomics Analyses Reveal High Induction of the Phenolamide Pathway in Tomato Plants Attacked by the Leafminer .

Roumani M, Le Bot J, Boisbrun M, Magot F, Péré A, Robin C, Hilliou F, Larbat R

Metabolites. 2022 05 26;12(6):

Targeting the Angiotensin II Type 1 Receptor in Cerebrovascular Diseases: Biased Signaling Raises New Hopes.

Delaitre C, Boisbrun M, Lecat S, Dupuis F

Int J Mol Sci. 2021 Jun 23;22(13):

New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.

Dupommier D, Muller C, Comoy C, Mazerbourg S, Bordessa A, Piquard E, Pawlak M, Piquard F, Martin H, De Fays E, Grandemange S, Flament S, Boisbrun M

Eur J Med Chem. 2019 Dec 4;187:111939

Synthesis and Antibacterial Evaluation of Bis-thiazolium, Bis-imidazolium, and Bis-triazolium Derivatives.

Thomas B, Duval RE, Fontanay S, Varbanov M, Boisbrun M

ChemMedChem. 2019 May 22;:

Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor.

Meyer M, Foulquier S, Dupuis F, Flament S, Grimaud L, Henrion D, Lartaud I, Monard G, Grillier-Vuissoz I, Boisbrun M

Eur J Med Chem. 2018 Aug 31;158:334-352

Biotinylation enhances the anticancer effects of 15d‑PGJ2 against breast cancer cells.

Colin C, Meyer M, Cerella C, Kleinclauss A, Monard G, Boisbrun M, Diederich M, Flament S, Grillier-Vuissoz I, Kuntz S

Int. J. Oncol.. 2018 Mar 28;:

Pro-apoptotic effect of Δ2-TGZ in "claudin-1-low" triple-negative breast cancer cells: involvement of claudin-1.

Geoffroy M, Kleinclauss A, Grandemange S, Hupont S, Boisbrun M, Flament S, Grillier-Vuissoz I, Kuntz S

Breast Cancer Res. Treat.. 2017 Jul;:

Δ2-Troglitazone promotes cytostatic rather than pro-apoptotic effects in breast cancer cells cultured in high serum conditions.

Berthe A, Flament S, Grandemange S, Zaffino M, Boisbrun M, Mazerbourg S

Cell Cycle. 2016 Dec;15(24):3402-3412

Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?

Mazerbourg S, Kuntz S, Grillier-Vuissoz I, Berthe A, Geoffroy M, Flament S, Bordessa A, Boisbrun M

Curr Top Med Chem. 2016 ;16(19):2115-24

Energy restriction mimetic agents to target cancer cells: comparison between 2-deoxyglucose and thiazolidinediones.

Kuntz S, Mazerbourg S, Boisbrun M, Cerella C, Diederich M, Grillier-Vuissoz I, Flament S

Biochem Pharmacol. 2014 Nov 1;92(1):102-11

Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.

Bordessa A, Colin-Cassin C, Grillier-Vuissoz I, Kuntz S, Mazerbourg S, Husson G, Vo M, Flament S, Martin H, Chapleur Y, Boisbrun M

Eur J Med Chem. 2014 Aug 18;83:129-40

Synthesis and Anti-Proliferative Activity of New Biphenyle-Benzylidenethiazolidine-2,4-dione Bis-Adducts Containing Various Heterocyclic Cores.

Meyer M, Kuntz S, Grillier-Vuissoz I, Martin H, Richert L, Flament S, Chapleur Y, Boisbrun M

Lett Drug Des Discov. 2014 Mar;11(3):256-64.